A. Ari Hakimi

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

A post-translational regulatory map of chronic antigen-driven human T cell dysfunction

Dissecting the molecular landscape of fumarate hydratase-deficient RCC: towards precision oncology.

Convergent genomic and molecular features predict risk of metachronous metastasis in clear cell renal cell carcinoma.

Inflammation-Driven Field Cancerization in End-Stage Kidney Disease.

Mechanistic insights make cancer cachexia a targetable syndrome.

Biomarkers for renal cell carcinoma - a pragmatic approach.

Spatial atlas of diabetic kidney disease reveals a B cell-rich subgroup.

Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data.

The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs.

The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs

A health-system-scale, episode-resolved multimodal atlas of cancer cachexia

Immune Checkpoint Blockade Response in Mucinous Tubular and Spindle Cell Carcinoma.

Clinical and Molecular Characterization of KRAS-Mutated Renal Cell Carcinoma.

Data from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade

Radiomic biomarkers associated with immune checkpoint blockade response for advanced renal cell carcinoma

MLH1 Mismatch Repair Deficiency Predicts Exceptional Response to Immune Checkpoint Inhibition in Clear-cell Renal Cell Carcinoma

Supplementary Tables S1-S5 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade

Supplementary Figures S1-S3 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade

Supplementary Tables S6-S8 from Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade

Obesity-dependent selection of driver mutations in cancer.

Radiodensities of Skeletal Muscle and Visceral Adipose Tissues Are Prognostic Factors in Clear-Cell Renal Cell Carcinoma.

Genomic ancestry in kidney cancer: Correlations with clinical and molecular features.

Data from Radiodensities of Skeletal Muscle and Visceral Adipose Tissues Are Prognostic Factors in Clear-Cell Renal Cell Carcinoma

Supplementary Table S1 from Radiodensities of Skeletal Muscle and Visceral Adipose Tissues Are Prognostic Factors in Clear-Cell Renal Cell Carcinoma

Supplementary Table S2 from Radiodensities of Skeletal Muscle and Visceral Adipose Tissues Are Prognostic Factors in Clear-Cell Renal Cell Carcinoma

Supplementary Table S3 from Radiodensities of Skeletal Muscle and Visceral Adipose Tissues Are Prognostic Factors in Clear-Cell Renal Cell Carcinoma

Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.

Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma

A multimodal atlas of tumour metabolism reveals the architecture of gene–metabolite covariation